Supplementary Figure S2 from Cell-free Tumor Microparticle Vaccines Stimulate Dendritic Cells Via Cgas/sting Signaling

Huafeng Zhang,Ke Tang,Yi Zhang,Rujiang Ma,Jingwei Ma,Yong Li,Shunqun Luo,Xiaoyu Liang,Tiantian Ji,Zhichao Gu,Jinzhi Lu,He Wang,Xuetao Cao,Yonghong Wan,Bo Huang

DOI: https://doi.org/10.1158/2326-6066.22538207

2023-01-01

Abstract:Tumor cells-derived microparticles were efficiently taken up by DCs, resulting in T cells proliferation.

What problem does this paper attempt to address?

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Mengqiu Wang,Pinglong Xu,Qirou Wu

DOI: https://doi.org/10.3724/zdxbyxb-2023-0482

2024-01-01

Abstract:Targeting cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway is a promising strategy for tumor treatment. The pattern recognition receptor cGAS identifies dsDNA and catalyzes the formation of a second messenger 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), activating the downstream interferons and pro-inflammatory cytokines through the adaptor protein STING. Notably, in tumor immune microenvironment, key components of cGAS-STING pathway are transferred among neighboring cells. The intercellular transmission under these contexts serves to sustain and amplify innate immune responses while facilitating the emergence of adaptive immunity. The membrane-based system, including extracellular vesicles transport, phagocytosis and membrane fusion transmit dsDNA, cGAMP and activated STING, enhances the immune surveillance and inflammatory responses. The membrane proteins, including a specific protein channel and intercellular gap junctions, transfer cGAMP and dsDNA, which are crucial to regulate immune responses. The ligand-receptor interactions for interferon transmission amplifies the anti-tumor response. This review elaborates on the regulatory mechanisms of cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment, explores how these mechanisms modulate immunological processes and discusses potential interventions and immunotherapeutic strategies targeting these signaling cascades.
[Infant leukemia with t(1;22) presenting proliferation of erythroid and megakaryocytic cell lineages].

M. Oshima,T. Fukushima,K. Koike,C. Hoshida,I. Izumi,M. Tsuchida

1999-03-01

Abstract:We report a case of infant leukemia with the proliferation of both erythroblast and megakaryoblast lineages. The blasts became double-positive for both erythroblastic and megakaryoblastic surface markers at the time of bone marrow relapse. A 9-month-old girl was admitted to our hospital presenting chiefly poor with weight gain and anemia. She also had splenomegaly, pleural effusion, leukocytosis, and thrombocytopenia. A bone marrow specimen showed 53.2% erythroblasts (PAS positive, alpha-NA positive, CD41 negative, MPO negative) and 20.4% megakaryoblasts with marked cytoplasmic blebs. We examined specimens by two-color flow cytometric analysis. At the onset, CD41+ glycophorin A- fraction and CD41- glycophorin A+ fraction were two major components. At the bone marrow relapse, the majority of blasts had altered to double-positive. Chromosomal analysis showed t (1; 22) (p13; q13), which has been reported to be specific for acute megakaryoblastic leukemia (M7) in infants. We reasoned that a leukemia had occurred in this patient at a progenitor cell level common to both erythroid and megakaryocytic lineages.
STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

Jian Wang,Suxin Li,Maggie Wang,Xu Wang,Shuqing Chen,Zhichen Sun,Xiubao Ren,Gang Huang,Baran D. Sumer,Nan Yan,Yang-Xin Fu,Jinming Gao

DOI: https://doi.org/10.1101/2024.01.02.573934

2024-01-09

Abstract:Stimulator of interferon genes (STING) is an immune adaptor protein that senses cyclic GMP-AMP (cGAMP) in response to self or microbial cytosolic DNA as a danger signal. STING is ubiquitously expressed in diverse cell populations including cancer cells with distinct cellular functions such as activation of type I interferons, autophagy induction, or triggering apoptosis. It is not well understood whether and which subsets of immune cells, stromal cells, or cancer cells are particularly important for STING-mediated antitumor immunity. Here using a polymeric STING-activating nanoparticle (PolySTING) with a “shock-and-lock” dual activation mechanism, we show type 1 conventional dendritic cell (cDC1) is essential for STING-mediated rejection of multiple established and metastatic murine tumors. STING status in the host but not in the cancer cells ( ) is important for antitumor efficacy. Specific depletion of cDC1 ( ) or STING deficiency in cDC1 ( ) abolished PolySTING efficacy, whereas depletion of other myeloid cells had little effect. Adoptive transfer of wildtype cDC1 in mice restored antitumor efficacy while transfer of cDC1 with STING or IRF3 deficiency failed to rescue. PolySTING induced a specific chemokine signature in wildtype but not mice. Multiplexed immunohistochemistry analysis of STING-activating cDC1s in resected tumors correlates with patient survival while also showing increased expressions after neoadjuvant pembrolizumab therapy in non-small cell lung cancer patients. Therefore, we have defined that a subset of myeloid cells is essential for STING-mediated antitumor immunity with associated biomarkers for prognosis.

Immunology
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

Guohao Li,Xiangqian Zhao,Zuda Zheng,Hucheng Zhang,Yundi Wu,Yangkun Shen,Qi Chen

DOI: https://doi.org/10.1007/s00018-024-05191-6

IF: 8

2024-03-22

Cellular and Molecular Life Sciences

Abstract:Type I interferons (IFN-I) play pivotal roles in tumor therapy for three decades, underscoring the critical importance of maintaining the integrity of the IFN-1 signaling pathway in radiotherapy, chemotherapy, targeted therapy, and immunotherapy. However, the specific mechanism by which IFN-I contributes to these therapies, particularly in terms of activating dendritic cells (DCs), remains unclear. Based on recent studies, aberrant DNA in the cytoplasm activates the cyclic GMP-AMP synthase (cGAS)- stimulator of interferon genes (STING) signaling pathway, which in turn produces IFN-I, which is essential for antiviral and anticancer immunity. Notably, STING can also enhance anticancer immunity by promoting autophagy, inflammation, and glycolysis in an IFN-I-independent manner. These research advancements contribute to our comprehension of the distinctions between IFN-I drugs and STING agonists in the context of oncology therapy and shed light on the challenges involved in developing STING agonist drugs. Thus, we aimed to summarize the novel mechanisms underlying cGAS-STING-IFN-I signal activation in DC-mediated antigen presentation and its role in the cancer immune cycle in this review.

cell biology,biochemistry & molecular biology
Glycolysis drives STING signaling to facilitate dendritic cell antitumor function

Zhilin Hu,Xiaoyan Yu,Rui Ding,Ben Liu,Chuanjia Gu,Xiu-Wu Pan,Qiaoqiao Han,Yuerong Zhang,Jie Wan,Jiayuan Sun,Qiang Zou,Xin-Gang Cui

DOI: https://doi.org/10.1172/jci166031

IF: 19.456

2023-04-04

Journal of Clinical Investigation

Abstract:Activation of STING signaling in DCs promotes antitumor immunity. Aerobic glycolysis is a metabolic hallmark of activated DCs, but how the glycolytic pathway intersects with STING signaling in tumor-infiltrating DCs remains elusive. Here, we show that glycolysis drives STING signaling to facilitate DC-mediated antitumor immune responses. Tumor-infiltrating DCs exhibited elevated glycolysis, and blockade of glycolysis by DC-specific Ldha / Ldhb double deletion resulted in defective antitumor immunity. Mechanistically, glycolysis augmented ATP production to boost STING activation and STING-dependent DC antitumor functions. Moreover, DC-intrinsic STING activation accelerated HIF-1α–mediated glycolysis and established a positive feedback loop. Importantly, glycolysis facilitated STING-dependent DC activity in tissue samples from patients with non–small cell lung cancer. Our results provide mechanistic insight into how the crosstalk of glycolytic metabolism and STING signaling enhances DC antitumor activity and can be harnessed to improve cancer therapies.

medicine, research & experimental
Targeting STING with Cyclic Di-Gmp Greatly Augmented Immune Responses of Glycopeptide Cancer Vaccines

Jun-Jun Wu,Wen-Hao Li,Pu-Guang Chen,Bo-Dou Zhang,Hong-Guo Hu,Qian-Qian Li,Lang Zhao,Yong-Xiang Chen,Yu-Fen Zhao,Yan-Mei Li

DOI: https://doi.org/10.1039/c8cc04860f

IF: 4.9

2018-01-01

Chemical Communications

Abstract:Cyclic di-GMP (CDG) was applied to MUC1 glycopeptide-based cancer vaccines with physical mixing and built-in (at 2-OH of CDG) strategies for activating the STING pathway. CDG in both strategies behaved as a potent immunostimulant and contributed to high titers of IgG antibodies and the expression of multiple cytokines.
Abstract LB114: STING licensing of type I dendritic cells potentiates antitumor immunity

Jian Wang,Suxin Li,Maggie Wang,Xu Wang,Shuqing Chen,Zhichen Sun,Xiubao Ren,Gang Huang,Baran D. Sumer,Nan Yan,Yang-Xin Fu,Jinming Gao

DOI: https://doi.org/10.1158/1538-7445.am2024-lb114

IF: 11.2

2024-04-07

Cancer Research

Abstract:Stimulator of interferon genes (STING) is an immune adaptor protein that senses cyclic GMP-AMP (cGAMP) in response to self or microbial cytosolic DNA as a danger signal. STING is ubiquitously expressed in diverse cell populations including cancer cells with distinct cellular functions such as activation of type I interferons, autophagy induction, or triggering apoptosis. It is not well understood whether and which subsets of immune cells, stromal cells, or cancer cells are particularly important for STING-mediated antitumor immunity. Here using a polymeric STING-activating nanoparticle (PolySTING) with a "shock-and-lock" dual activation mechanism, we show type 1 conventional dendritic cell (cDC1) is essential for STING-mediated rejection of multiple established and metastatic murine tumors. STING status in the host but not in the cancer cells (Tmem173− / − ) is important for antitumor efficacy. Specific depletion of cDC1 (Batf3− / − ) or STING deficiency in cDC1 (XCR1creSTINGfl/fl ) abolished PolySTING efficacy, whereas depletion of other myeloid cells had little effect. Adoptive transfer of wildtype cDC1 in Batf3− / − mice restored antitumor efficacy while transfer of cDC1 with STING or IRF3 deficiency failed to rescue. PolySTING induced a specific chemokine signature in wildtype but not Batf3− / − mice. Multiplexed immunohistochemistry analysis of STING-activating cDC1s in resected tumors correlates with patient survival while also showing increased expressions after neoadjuvant pembrolizumab therapy in non-small cell lung cancer patients. Therefore, we have defined that a subset of myeloid cells is essential for STING-mediated antitumor immunity with associated biomarkers for prognosis. Citation Format: Jian Wang, Suxin Li, Maggie Wang, Xu Wang, Shuqing Chen, Zhichen Sun, Xiubao Ren, Gang Huang, Baran D. Sumer, Nan Yan, Yang-Xin Fu, Jinming Gao. STING licensing of type I dendritic cells potentiates antitumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB114.

oncology
Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402073

2023-01-01

Abstract:Involvement of CD4+ T cells in the induction of antitumor activity by CCDC134.
Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402076.v1

2023-01-01

Abstract:Potent antitumor activity of CCDC134 in vivo.
STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy

Nguyen Thi Nguyen,Xuan Thien Le,Woo Tak Lee,Yong Taik Lim,Kyung Taek Oh,Eun Seong Lee,Han-Gon Choi,Yu Seok Youn

DOI: https://doi.org/10.1016/j.bioactmat.2024.09.002

2024-09-06

Abstract:Recently, nanovaccine-based immunotherapy has been robustly investigated due to its potential in governing the immune response and generating long-term protective immunity. However, the presentation of a tumor peptide-major histocompatibility complex to T lymphocytes is still a challenge that needs to be addressed for eliciting potent antitumor immunity. Type 1 conventional dendritic cell (cDC1) subset is of particular interest due to its pivotal contribution in the cross-presentation of exogenous antigens to CD8+ T cells. Here, the DC-derived nanovaccine (denoted as Si9GM) selectively targets cDC1s with marginal loss of premature antigen release for effective stimulator of interferon genes (STING)-mediated antigen cross-presentation. Bone marrow dendritic cell (BMDC)-derived membranes, conjugated to cDC1-specific antibody (αCLEC9A) and binding to tumor peptide (OVA257-264), are coated onto dendrimer-like polyethylenimine (PEI)-grafted silica nanoparticles. Distinct molecular weight-cargos (αCLEC9A-OVA257-264 conjugates and 2'3'-cGAMP STING agonists) are loaded in hierarchical center-radial pores that enables lysosome escape for potent antigen-cross presentation and activates interferon type I, respectively. Impressively, Si9GM vaccination leads to the upregulation of cytotoxic T cells, a reduction in tumor regulatory T cells (Tregs), M1/M2 macrophage polarization, and immune response that synergizes with αPD-1 immune checkpoint blockade. This nanovaccine fulfills a dual role for both direct T cell activation as an artificial antigen-presenting cell and DC subset maturation, indicating its utility in clinical therapy and precision medicine.
Enhanced Antitumor Effects of Tumor Antigen-Pulsed Dendritic Cells by Their Transfection with GM-CSF Gene.

Xuetao Cao,Weiping Zhang,Shihua Ma,Minghui Zhang,Jianli Wang,Tianxing Ye

DOI: https://doi.org/10.1007/bf03183594

1997-01-01

Science in China Series C Life Sciences

Abstract:To investigate the biological characterization and antitumor activities of GM-CSF gene-transfected dendritic cells, the splenic dendritic cells were infected with GM-CSF recombinant replication-deficient adenovirusesin vitro. Their enhanced expression of B7 was demonstrated by FACS analysis, and more potent stimulatory activity was confirmed by allogeneic MLR. Immunization of dendritic cells pulsed with irradiated B16 melanoma cells induced significant CTL and enabled host to resist the challenge of wild-type B16 cells. When they were transfected with GM-CSF gene subsequently, the induced CTL activity was higher, and the produced protection against B16 cell challenge and therapeutic effect on the mice with preestablished pulmonary metastases more effective. These data suggest that the dendritic cells pulsed with tumor antigen then transfected with GM-CSF gene can be used as an effective vaccine in tumor immunotherapy.
Supplemental Figure S2 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402082

2023-01-01

Abstract:CCDC134 has no apparent effect on activation, effector function and proliferation of mouse CD4+ T cells.
Γδ T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-β Signaling Pathways.

Jing Luo,Shengli Wang,Quanli Yang,Qianqian Fu,Chuyun Zhu,Tao Li,Shuxian Yang,Yin Zhao,Rong Guo,Xiaosong Ben,Yuzhen Zheng,Sitao Li,Guang Yang,Hongru Zhang,Hui Xiao,Zhengfan Jiang,Nan Yan,Dieter Kabelitz,Guodong Sun,Zvi Granot,Ligong Lu,Fuping You,Jianlei Hao,Zhinan Yin

DOI: https://doi.org/10.1002/advs.202404432

2024-01-01

Abstract:The STING pathway plays a critical role in tumor immunosurveillance. However, the precise mechanisms by which STING regulates gamma delta (γδ) T cell function during tumor progression remain unclear. Herein, we find that tumor-derived cyclic GMP-AMP (cGAMP) activates a distinct STING pathway by inducing TBK1-mediated phosphorylation of Eomes in γδ T cells during the early stage of tumor development is demonstrated. This activation leads to interferon-gamma (IFN-γ) production and consequent tumor surveillance. However, at advanced stages of tumor progression, the accumulation of immune-suppressive cytokine transforming growth factor-beta (TGF-β) downregulates STING levels, compromising the function of γδ T cells. Notably, the synergism between TGF-β inhibition and STING agonists effectively counteracts the immunosuppressive tumor microenvironment, thereby augmenting the antitumoral effects of γδ T cells. These findings present a novel mechanism involving STING-mediated IFN-γ production in γδ T cells and hold significant implications for the development of potent immunotherapeutic approaches against cancer.
Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death

Yawen Guo,Ruijie Qian,Zijie Li,Tingting Lv,Chunwang Yang,Wen Li,Teng Pan,Xiaoming Hou,Zhiyu Wang

DOI: https://doi.org/10.1016/j.lfs.2024.122687

IF: 6.78

2024-05-09

Life Sciences

Abstract:Aims Checkpoint blockade immunotherapy is a promising therapeutic modality that has revolutionized cancer treatment; however, the therapy is only effective on a fraction of patients due to the tumor environment. In tumor immunotherapy, the cGAS-STING pathway is a crucial intracellular immune response pathway. Therefore, this study aimed to develop an immunotherapy strategy based on the cGAS-STING pathway. Materials and methods The physicochemical properties of the nanoparticles EM@REV@DOX were characterized by TEM, DLS, and WB. Subcutaneous LLC xenograft tumors were used to determine the biodistribution, antitumor efficacy, and immune response. Blood samples and tissues of interest were harvested for hematological analysis and H&E staining. Significance Overall, our designed nanovesicles provide a new perspective on tumor immunotherapy by ICD and cGAS-STING pathway, promoting DCs maturation, macrophage polarization, and activating T cells, offering a meaningful strategy for accelerating the clinical development of immunotherapy. Key findings EM@REV@DOX accumulated in the tumor site through EPR and homing targeting effect to release REV and DOX, resulting in DNA damage and finally activating the cGAS-STING pathway, thereby promoting DCs maturation, macrophage polarization, and activating T cells. Additionally, EM@REV@DOX increased the production of pro-inflammatory cytokines (e.g., TNF-α and IFN-β). As a result, EM@REV@DOX was effective in treating tumor-bearing mice and prolonged their lifespans. When combined with αPD-L1, EM@REV@DOX significantly inhibited distant tumor growth, extended the survival of mice, and prevented long-term postoperative tumor metastasis, exhibiting great potential in antitumor immunotherapy.

pharmacology & pharmacy,medicine, research & experimental
Abstract B12: T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy

Aida S. Hansen,Lea S. Jensen,Kristoffer G. Ryttersgaard,Christian Krapp,Jesper Just,Kasper L. Joensson,Anders Etzerodt,Bent W. Deleuran,Martin R. Jakobsen

DOI: https://doi.org/10.1158/2326-6074.tumimm22-b12

IF: 10.1

2022-12-03

Cancer Immunology Research

Abstract:Despite recent years advancement reported for cancer immunotherapies within multiple cancer types, we still see a large group of patients failing to respond to treatment. Activation of the innate immune pathway controlled by STimulator of INterferon Genes (STING) has been considered as an attractive target for boosting cancer immunotherapy. Extracellular vesicles (EVs) are key players in shaping immune responses and are proposed to provide a danger signal for antigen-presenting cells. Here, we hypothesize that CD4+ T-cell derived EVs (T-EVs) enhance innate immune cells function, such as macrophages, by priming the STING signaling pathway. We purified T-EVs from aCD3/aCD28 stimulated CD4+ T cells by differential ultracentrifugation, and primed macrophages with these prior to stimulation with STING agonists. Subsequent activation was measured by induction of type I Interferons and phosphorylation of signaling molecules within the STING pathway. We further explored the in vivo efficacy of combining T-EVs priming and STING agonists in tumor bearing mice models. We found that T-EVs sensitizes macrophages to respond more potently to STING activation. Importantly, this was independent on both surface-associated and intravesicular DNA. The priming of STING signaling was largely induced by IFNγ and TNFα carried by the T-EVs. We further showed that the T-EVs enhances the efficacy of STING agonist stimulation, by controlling tumor growth in syngeneic MC38 tumor models. Our work support that T-EVs can disrupt the immune suppressive tumor microenvironment by reprogramming macrophages to a pro-inflammatory phenotype, and priming them for a robust immune response towards STING activation. Citation Format: Aida S. Hansen, Lea S. Jensen, Kristoffer G. Ryttersgaard, Christian Krapp, Jesper Just, Kasper L. Joensson, Anders Etzerodt, Bent W. Deleuran, Martin R. Jakobsen. T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr B12.

oncology,immunology
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

Junhua Mai,Zhaoqi Li,Xiaojun Xia,Jingxin Zhang,Jun Li,Haoran Liu,Jianliang Shen,Maricela Ramirez,Feng Li,Zheng Li,Kenji Yokoi,Xuewu Liu,Elizabeth A. Mittendorf,Mauro Ferrari,Haifa Shen

DOI: https://doi.org/10.1002/advs.202100166

IF: 15.1

2021-04-15

Advanced Science

Abstract:Success in anticancer immune therapy relies on stimulation of tumor antigen‐specific T lymphocytes and effective infiltration of the T cells into tumor tissue. Here, a therapeutic vaccine that promotes proliferation and tumor infiltration of antigen‐specific T cells in both inflamed and noninflamed tumor types is described. The vaccine consists of STING agonist 2′3′‐cGAMP, TLR9 ligand CpG, and tumor antigen peptides that are loaded into nanoporous microparticles (μGCVax). μGCVax is effective in inhibiting lung metastatic melanoma, primary breast cancer, and subcutaneous colorectal cancer in their respective murine models, including functional cure of HER2‐positive breast cancer. Mechanistically, μGCVax potently stimulates type I interferon expression in dendritic cells, and promotes CD8+ and CD103+ dendritic cell maturation and migration to lymph nodes and other lymphatic tissues. Antitumor responses are dependent on TLR9 and interferon α/β receptor signaling, and to a less extent on STING signaling. These results demonstrate a high potential for μGCVax in mediating antitumor immunity in personalized cancer therapy.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation

Bo-Dou Zhang,Jun-Jun Wu,Wen-Hao Li,Hong-Guo Hu,Lang Zhao,Pei-Yang He,Yu-Fen Zhao,Yan-Mei Li

DOI: https://doi.org/10.1007/s12274-022-4282-x

IF: 9.9

2022-04-18

Nano Research

Abstract:Immunostimulatory therapies based on pattern recognition receptors (PRRs) have emerged as an effective approach in the fight against cancer, with the ability to recruit tumor-specific lymphocytes in a low-immunogenicity tumor environment. The agonist cyclic dinucleotides (CDNs) of the stimulator of interferon gene (STING) are a group of very promising anticancer molecules that increase tumor immunogenicity by activating innate immunity. However, the tumor immune efficacy of CDNs is limited by several factors, including relatively narrow cytokine production, inefficient delivery to STING, and rapid clearance. In addition, a single adjuvant molecule is unable to elicit a broad cytokine response and thus cannot further amplify the anticancer effect. To address this problem, two or more agonist molecules are often used together to synergistically enhance immune efficacy. In this work, we found that a combination of the STING agonist CDGSF and the Toll-like receptor 7/8 (TLR7/8) agonist 522 produced a broader cytokine response. Subsequently, we developed multicomponent nanovaccines (MCNVs) consisting of a PC7A polymer as a nanocarrier encapsulating the antigen OVA and adjuvant molecules. These MCNVs activate bone marrow-derived dendritic cells (BMDCs) to produce multiple proinflammatory factors that promote antigen cross-presentation to stimulate specific antitumor T-cell responses. In in vivo experiments, we observed that MCNVs triggered a strong T-cell response in tumor-infiltrating lymphocytes, resulting in significant tumor regression and, notably, a 100% survival rate in mice through 25 days without other partnering therapies. These data suggest that our nanovaccines have great potential to advance cancer immunotherapy with increased durability and potency.

materials science, multidisciplinary,chemistry, physical,physics, applied,nanoscience & nanotechnology
The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy

Ana Ribeiro,Theresa Neuper,Jutta Horejs-Hoeck

DOI: https://doi.org/10.2147/ijn.s477320

IF: 7.033

2024-10-23

International Journal of Nanomedicine

Abstract:Ana RS Ribeiro, 1, 2 Theresa Neuper, 1– 3 Jutta Horejs-Hoeck 1– 3 1 Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria; 2 Cancer Cluster Salzburg (CCS), Salzburg, 5020, Austria; 3 Center for Tumor biology and Immunology (CTBI), Salzburg, 5020, Austria Correspondence: Jutta Horejs-Hoeck, Department of Biosciences and Medical Biology, Paris-Lodron University Salzburg, Hellbrunner Strasse 34, Salzburg, 5020, Austria, Tel +43(0)662 8044 5709, Email The signaling pathway that comprises cyclic guanosine monophosphate–adenosine monophosphate (cGAMP or GMP-AMP) synthase (cGAS) and Stimulator of Interferon Genes (STING) is emerging as a druggable target for immunotherapy, with tumor-resident dendritic cells (DC) playing a critical role in mediating its effects. The STING receptor is part of the DNA-sensing cellular machinery, that can trigger the secretion of pro-inflammatory mediators, priming effector T cells and initiating specific antitumor responses. Yet, recent studies have highlighted the dual role of STING activation in the context of cancer: STING can either promote antitumor responses or enhance tumor progression. This dichotomy often depends on the cell type in which cGAS-STING signaling is induced and the activation mode, namely acute versus chronic. Of note, STING activation at the DC level appears to be particularly important for tumor eradication. This review outlines the contribution of the different conventional and plasmacytoid DC subsets and describes the mechanisms underlying STING-mediated activation of DCs in cancer. We further highlight how the STING pathway plays an intricate role in modulating the function of DCs embedded in tumor tissue. Additionally, we discuss the strategies being employed to harness STING activation for cancer treatment, such as the development of synthetic agonists and nano-based delivery systems, spotlighting the current techniques used to prompt STING engagement specifically in DCs. Keywords: dendritic cell, cGAS-STING pathway, cancer immunotherapy, nanoparticle The paradigm of natural antitumor immunity involves the recognition, processing and presentation of cancer-associated antigens by dendritic cells (DCs) on major histocompatibility (MHC) complexes, triggering effective T cell-mediated antitumor immunity that results in killing of the cancer cells. 1–4 Accordingly, DCs are highly specialized tissue-scanning cells equipped with a plethora of receptors to detect damage- or pathogen-associated molecular patterns (DAMPs or PAMPs). Although the immune system's task of filtering and responding to onco-signals emanating from cancerous tissue is an exceedingly complex one, the wide range of innate receptors expressed by DCs enables them to effectively recognize several by-products associated with tumor growth, such as tumor-derived DNA present in the tumor microenvironment (TME). 5–7 The cGAS-STING pathway is an innate DNA-sensing mechanism which was originally described to mediate protective immune responses against infections but was recently found to play a crucial role in driving antitumor immunity. In particular, activation of STING signaling in DCs has the potential to generate spontaneous as well as long-lasting and highly specific antitumor immunity. 8–10 This review focuses on the contribution of individual DC subsets to cancer defense and explores emerging developments in STING-mediated activation of DCs for novel cancer therapeutics. The cGAS-cGAMP-STING signaling pathway, discovered in 2013, is a promising therapeutic target to enhance antitumor immunity. Its activation induces an inflammatory response that converts "cold" tumors into "hot" tumors, ie, cancers that have higher infiltration of immune cells and consequently are more likely to exhibit higher response rates to currently used immunotherapies such as immune checkpoint inhibitors (ICI). 8,9,11 STING is a ubiquitous intracellular receptor that is located in the endoplasmic reticulum membrane and activated by binding of the agonist cGAMP. cGAMP is a naturally occurring cyclic dinucleotide (CDN) produced when the enzyme cGAS detects intracellular nucleic acids. Upon binding cGAMP, STING dimerizes and undergoes vesicular trafficking to the Golgi. This triggers downstream signaling which involves activation of TANK binding kinase 1 (TBK1), phosphorylation of interferon (IFN) regulatory factor 3 (IRF3), and induction of nuclear factor kappa B (NF-κB). 12,13 As a result, type I IFNs (IFN I) are upregulated, leading to expression and secretion of pro-inflammatory factors that can affect the TME and influence disease progression. 14–16 In cancer cells, the cGAS-STING pathway is frequently activated due to genomic instabi -Abstract Truncated-

pharmacology & pharmacy,nanoscience & nanotechnology
Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment

Susam Lee,Kyeong Hee Hong,Heewon Park,JongHoon Ha,Seung Eon Lee,Dong Jin Park,Seong Dong Jeong,Seohyeon Kim,Dahae Kim,JiWon Ahn,Han-Woong Lee,Won-Gun Koh,Sang-Jun Ha,Yeu-Chun Kim

DOI: https://doi.org/10.1016/j.jconrel.2024.07.004

Abstract:Immunogenic cell death (ICD) holds the potential for in situ tumor vaccination while concurrently eradicating tumors and stimulating adaptive immunity. Most ICD inducers, however, elicit insufficient immune responses due to negative feedback against ICD biomarkers, limited infiltration of antitumoral immune cells, and the immunosuppressive tumor micro-environment (TME). Recent findings highlight the pivotal roles of stimulators of interferon gene (STING) activation, particularly in stimulating antigen-presenting cells (APCs) and TME reprogramming, addressing ICD limitations. Herein, we introduced 'tumor phagocytosis-driven STING activation', which involves the activation of STING in APCs during the recognition of ICD-induced cancer cells. We developed a polypeptide-based nanocarrier encapsulating both doxorubicin (DOX) and diABZI STING agonist 3 (dSA3) to facilitate this hypothesis in vitro and in vivo. After systemic administration, nanoparticles predominantly accumulated in tumor tissue and significantly enhanced anticancer efficacy by activating tumor phagocytosis-driven STING activation in MC38 and TC1 tumor models. Immunological activation of APCs occurred within 12 h, subsequently leading to the activation of T cells within 7 days, observed in both the TME and spleen. Furthermore, surface modification of nanoparticles with cyclic RGD (cRGD) moieties, which actively target integrin αvβ3, enhances tumor accumulation and eradication, thereby verifying the establishment of systemic immune memory. Collectively, this study proposes the concept of tumor phagocytosis-driven STING activation and its effectiveness in generating short-term and long-term immune responses.
Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine

Chunju Fang,Fei Mo,Li Liu,Jing Du,Min Luo,Ke Men,Feifei Na,Wei Wang,Hanshuo Yang,Xiawei Wei

DOI: https://doi.org/10.1038/s41423-020-0456-1

2020-05-12

Cellular and Molecular Immunology

Abstract:Abstract Exposure to ionizing radiation, a physical treatment that inactivates live tumor cells, has been extensively applied to enhance the antitumor responses induced by cancer cell vaccines in both animal research and human clinical trials. However, the mechanisms by which irradiated cells function as immunogenic tumor vaccines and induce effective antitumor responses have not been fully explored. Here, we demonstrate that oxidized mitochondrial DNA (mtDNA) and stimulator of interferon genes (STING) signaling play a key roles in the enhanced antitumor effect achieved with an irradiated tumor cell vaccine. Elevations in ROS and oxidized mtDNA 8-OHG content could be induced in irradiated tumor cells. Oxidized mtDNA derived from irradiated tumor cells gained access to the cytosol of dendritic cells (DCs). Oxidized mtDNA, as a DAMP or adjuvant, activated the STING-TBK1-IRF3-IFN-β pathway in DCs, which subsequently cross-presented irradiated tumor cell-derived antigens to CD8 + T cells and elicited antitumor immunity. The results of our study provide insight into the mechanism by which an irradiated cell vaccine mediates antitumor immunity, which may have implications for new strategies to improve the efficacy of irradiated vaccines.

immunology

Supplementary Figure S2 from Cell-free Tumor Microparticle Vaccines Stimulate Dendritic Cells Via Cgas/sting Signaling

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

[Infant leukemia with t(1;22) presenting proliferation of erythroid and megakaryocytic cell lineages].

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

Glycolysis drives STING signaling to facilitate dendritic cell antitumor function

Targeting STING with Cyclic Di-Gmp Greatly Augmented Immune Responses of Glycopeptide Cancer Vaccines

Abstract LB114: STING licensing of type I dendritic cells potentiates antitumor immunity

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy

Enhanced Antitumor Effects of Tumor Antigen-Pulsed Dendritic Cells by Their Transfection with GM-CSF Gene.

Supplemental Figure S2 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Γδ T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-β Signaling Pathways.

Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death

Abstract B12: T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy

Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation

The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy

Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment

Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine